Loading data for IMNM — first visit, this takes a few seconds.

알림

Immunome Inc. (IMNM)

NasdaqCM: IMNM · 실시간 가격 · USD

28.15

+0.59 (2.14%)

종가 기준: Aug 18, 2026, 8:00 PM

2.14% (1D)

데이터 없음

매수호가	20.12
시가총액	3.13B
매출 (ttm)	n/a
순이익 (ttm)	-254.32M
베타	2.12
EPS (ttm)	-2.55
P/E (ttm)	n/a
선행 P/E	-11.12
P/B (ttm)	5.95
P/S (ttm)	n/a
Earnings Date	Nov 5, 2026

매도호가	34.58
거래량	81,473
평균 거래량 (20일)	1,388,841
시가	27.99
전일 종가	27.56
일중 범위	27.62 - 28.26
52주 범위	8.66 - 28.62
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

IMNM 소개

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjug...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Oct 2, 2020

직원 수 247

상장 거래소 NasdaqCM

티커 IMNM

웹사이트 https://immunome.com

전체 기업 정보

재무 실적

2025년 Immunome의 매출은 6.94M로, 전년 9.04M 대비 -23.23% 감소했습니다. 순이익은 -212.39M로, -27.5% 감소했습니다.

재무제표

어닝 서프라이즈

Immunome가 Aug 11, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 -100.00% 전년 대비 감소.

EPS -0.65 예상치 하회 -0.15, 및 -25.00% 전년 대비 감소.

다음 실적 발표

Immunome Inc.의 실적 발표 예정일은 Nov 5, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1개월 전 · Motley Fool

What This Immunome Sale Means a Day Before a Big FDA Milestone

Barchas maintains 211,763 residual shares through direct and indirect holdings following execution under a Rule 10b5-1 trading plan adopted in March 2026.

1개월 전 · Zacks

Immunome Stock Up 32% in a Month: Here's What You Should Know

IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with an approval decision expected by April 2027.

2개월 전 · Zacks

4 Biotech Stocks Investors Should Watch in 2026

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli...

2개월 전 · Simply Wall St.

Immunome (IMNM) Is Down 12.7% After Phase 3 Varegacestat Data And FDA NDA Filing - Has The Bull Case Changed?

Immunome, Inc. recently reported detailed efficacy and safety results from its global Phase 3 RINGSIDE trial of varegacestat in progressing desmoid tumors, showing statistically significant benefits i...

2개월 전 · Investing.com

Barclays initiates oncology-focused biotechs with positive outlook

Investing.com -- Barclays initiated coverage of four small- and mid-cap biotechnology companies in a note to clients on Thursday, calling the stocks differentiated platform plays with the potential to...

2 페이지 중 1

Immunome Inc. (IMNM)